Search Results
- < Prev
1 of 1
- Next >
News Releases
-
May 16, 2013, 18:02 ET
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2013 UBS Global Healthcare Conference in New York at the Sheraton New York Hotel on Tuesday, May 21, 2013 at 10:00 a.m. Eastern time. The presentation will be...
More news about: Nektar Therapeutics
-
May 09, 2013, 16:15 ET
Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2013. Cash and investments in marketable securities at March 31, 2013 were $261.2 million as compared to $302.2 million at December 31, 2012. "We made great progress advancing two...
More news about: Nektar Therapeutics
-
May 02, 2013, 17:00 ET
Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2013 on Thursday, May 9, 2013, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results...
More news about: Nektar Therapeutics
-
Apr 17, 2013, 09:31 ET
Critical Alerts For Intel, Delta, Southern Copper, Lam Research, and Nektar Therapeutics Released By InvestorsObserver
InvestorsObserver issues critical PriceWatch Alerts for INTC, DAL, SCCO, LRCX, and NKTR. (Photo: http://photos.prnewswire.com/prnh/20120712/CG39046) To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at...
More news about: InvestorsObserver , Intel Corporation , Delta Air Lines Inc. , Southern Copper Corp. , Lam Research Corporation , Nektar Therapeutics
-
Apr 16, 2013, 05:00 ET
Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
Bayer HealthCare Pharmaceuticals Inc. announced today that patient enrollment is underway in its global Phase III trial program to evaluate the efficacy and safety of adjunctive aerosolized BAY41-6551 versus aerosolized placebo in the treatment of intubated and mechanically ventilated...
More news about: Bayer HealthCare Pharmaceuticals Inc. , Nektar Therapeutics
-
Apr 07, 2013, 13:00 ET
Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
Nektar Therapeutics (Nasdaq: NKTR) today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research (AACR) Annual Meeting. NKTR-214 is a new immunocytokine that is being developed as a...
More news about: Nektar Therapeutics
- < Prev
1 of 1
- Next >
Modify your Search
 |
Quickly search for PR Newswire releases by adding our plugin to your browser search |